AU2021265345A1 - Leriglitazone for treating lung inflammation and interstitial lung disease - Google Patents

Leriglitazone for treating lung inflammation and interstitial lung disease Download PDF

Info

Publication number
AU2021265345A1
AU2021265345A1 AU2021265345A AU2021265345A AU2021265345A1 AU 2021265345 A1 AU2021265345 A1 AU 2021265345A1 AU 2021265345 A AU2021265345 A AU 2021265345A AU 2021265345 A AU2021265345 A AU 2021265345A AU 2021265345 A1 AU2021265345 A1 AU 2021265345A1
Authority
AU
Australia
Prior art keywords
thiazolidine
dione
ethoxy
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021265345A
Other languages
English (en)
Inventor
Nuria IZQUIERDO USEROS
Sonia MARIA POLI
Marc Martinell Pedemonte
Maria Pilar Pizcueta Lalanza
Estefania TRAVER LÓPEZ
Anna VILALTA SAURA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Publication of AU2021265345A1 publication Critical patent/AU2021265345A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021265345A 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease Abandoned AU2021265345A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382356 2020-04-30
EP20382356.2 2020-04-30
PCT/IB2021/053651 WO2021220250A1 (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Publications (1)

Publication Number Publication Date
AU2021265345A1 true AU2021265345A1 (en) 2022-12-08

Family

ID=70779625

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021265345A Abandoned AU2021265345A1 (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Country Status (11)

Country Link
US (1) US20230172921A1 (cg-RX-API-DMAC7.html)
EP (1) EP4142720A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023525981A (cg-RX-API-DMAC7.html)
KR (1) KR20230035522A (cg-RX-API-DMAC7.html)
CN (1) CN116390725A (cg-RX-API-DMAC7.html)
AU (1) AU2021265345A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021951A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180351A1 (cg-RX-API-DMAC7.html)
IL (1) IL297771A (cg-RX-API-DMAC7.html)
MX (1) MX2022013021A (cg-RX-API-DMAC7.html)
WO (1) WO2021220250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
JP2026500743A (ja) * 2022-12-28 2026-01-08 ミノリックス セラピューティクス エセ.エレ. レリグリタゾンの最適投薬
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222272B1 (en) * 2008-08-07 2012-11-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US20120190637A1 (en) * 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
WO2011073662A1 (en) * 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
MX379710B (es) * 2016-12-01 2025-03-11 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.
MX2020013182A (es) * 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.

Also Published As

Publication number Publication date
EP4142720A1 (en) 2023-03-08
CN116390725A (zh) 2023-07-04
US20230172921A1 (en) 2023-06-08
MX2022013021A (es) 2023-01-16
IL297771A (en) 2022-12-01
CA3180351A1 (en) 2021-11-04
BR112022021951A2 (pt) 2022-12-13
JP2023525981A (ja) 2023-06-20
KR20230035522A (ko) 2023-03-14
WO2021220250A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
US20230172921A1 (en) Leriglitazone for treating lung inflammation and interstitial lung disease
US20230084300A1 (en) Prevention and treatment of infections including those caused by coronavirus
US20110295365A1 (en) Anti-viral compositions and methods for administration
US11364227B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
US20230157994A1 (en) New compositions and methods of treating covid-19 disease
US20240316083A1 (en) Medicament for prevention or treatment of rhinovirus infection
CA3166132A1 (en) Methods for prevention or treatment of virus-induced organ injury or failure with il-22 dimer
US20230021647A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
US20220288155A1 (en) Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
US20070099855A1 (en) Glycyrrhizin or derivatives thereof for for treating or preventing severe acute respiratory syndrome (sars)
Tutak et al. A patient presenting with ARDS after COVID-19 vaccination: a COVID-19 case report
JP2023512062A (ja) 関節の炎症を治療するためにモメロチニブを使用する方法
HK40096631A (en) Leriglitazone for treating lung inflammation and interstitial lung disease
EP4183396A1 (en) Use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia
EP4115885A1 (en) A pharmaceutical composition comprising bay 86-5277 and salts thereof for use in the treatment of viral infections and hyperinflammation
US20220017614A1 (en) Anti-IL6 Agent for Treating Coronavirus Infection
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
JP2023541921A (ja) Covid-19肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験(empacta)の結果
RU2837859C1 (ru) Лечение коронавирусной инфекции
Haw et al. TLR7 promotes smoke-induced lung damage through the activity of mast cell tryptase
JP2024138570A (ja) 肺線維症の治療および修復方法

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period